243 related articles for article (PubMed ID: 25504434)
1. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
De Giorgi U; Caroli P; Burgio SL; Menna C; Conteduca V; Bianchi E; Fabbri F; Carretta E; Amadori D; Paganelli G; Matteucci F
Oncotarget; 2014 Dec; 5(23):12448-58. PubMed ID: 25504434
[TBL] [Abstract][Full Text] [Related]
2. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
4. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
5. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
[TBL] [Abstract][Full Text] [Related]
6. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V; Scarpi E; Caroli P; Salvi S; Lolli C; Burgio SL; Menna C; Schepisi G; Testoni S; Gurioli G; Paganelli G; Casadio V; Matteucci F; De Giorgi U
Sci Rep; 2017 Nov; 7(1):15541. PubMed ID: 29138500
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of
Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
[TBL] [Abstract][Full Text] [Related]
8. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
Maines F; Caffo O; Donner D; Sperduti I; Bria E; Veccia A; Chierichetti F; Tortora G; Galligioni E
Future Oncol; 2016 Feb; 12(3):333-42. PubMed ID: 26768648
[TBL] [Abstract][Full Text] [Related]
9. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
12. Interim and end-treatment
García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
[TBL] [Abstract][Full Text] [Related]
13. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
15. Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.
Farnebo J; Wadelius A; Sandström P; Nilsson S; Jacobsson H; Blomqvist L; Ullén A
Medicine (Baltimore); 2016 Aug; 95(31):e4308. PubMed ID: 27495034
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
20. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H
Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
